Skip to main content

2021 Year in Review - Renal-Cell Carcinoma

In a retrospective study, active therapy conferred a survival benefit versus BSC for patients who have disease progression on both nivolumab and cabozantinib. Read More ›

Since the approval of dual immune checkpoint inhibition, real-world treatment patterns have evolved. Read More ›

Blood flow measured by dynamic contrast-enhanced computed tomography can predict survival with antiangiogenic treatment. Read More ›

In a retrospective study, lenvatinib with or without everolimus resulted in antitumor activity in patients who had received previous tyrosine kinase inhibitors and immunotherapy. Read More ›

Rechallenge with nivolumab after first-line immune checkpoint inhibition has moderate antitumor activity and acceptable tolerability. Read More ›

Stereotactic radiotherapy for oligoprogressive tumors while on oral systemic therapy delays time to treatment switch. Read More ›

A 14-mg starting dose of lenvatinib did not improve tolerability and had numerically worse efficacy than the approved 18-mg dose. Read More ›

In a phase 2 trial, cabozantinib tolerably improved outcomes in patients pretreated with immunotherapy. Read More ›

Page 1 of 2